CUE Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
7.9M
+38.5%
5.7M
-74.1%
21.9M
+921.0%
2.1M
-27.3%
3.0M
Cost of Revenue
0
0
0
0
0
Gross Profit
7.9M
+38.5%
5.7M
-74.1%
21.9M
+921.0%
2.1M
-27.3%
3.0M
Operating Expenses
95.6M
+765.8%
11.0M
-44.8%
20.0M
+106.2%
9.7M
-16.4%
11.6M
R&D
49.0M
+610.6%
6.9M
-58.3%
16.5M
+247.7%
4.8M
-39.9%
7.9M
SG&A
46.6M
+1021.5%
4.2M
+20.3%
3.5M
-30.1%
4.9M
+34.2%
3.7M
Operating Income
-87695000
-1538.2%
-5353000
-373.4%
2.0M
+126.0%
-7544000
+12.6%
-8635000
EBITDA
-87659000
-1727.4%
-4797000
-282.0%
2.6M
+135.3%
-7464000
+12.6%
-8536000
Net Income
-153067000
-2856.1%
-5178000
-426.7%
1.6M
+121.3%
-7448000
+12.2%
-8482000
EPS (Basic)
$-24.14
-2135.2%
$-1.08
-735.3%
$0.17
+108.1%
$-2.10
+21.3%
$-2.67
EPS (Diluted)
$-24.14
-2135.2%
$-1.08
-735.3%
$0.17
+108.1%
$-2.10
+21.3%
$-2.67
Shares (Diluted)
6.3M
+31.9%
4.8M
-47.1%
9.1M
+170.1%
3.4M
+5.7%
3.2M
Cue Biopharma (CUE) โ€” Financials